Fig. 2: Aspirin antiplatelet effect pathway. | npj Genomic Medicine

Fig. 2: Aspirin antiplatelet effect pathway.

From: A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications

Fig. 2

Aspirin is an inhibitor of cyclooxygenase (COX) that catalyses the transformation of arachidonic acid (AA) into prostaglandins G2 and H2. Thromboxane A2 (TXA2) is formed by thromboxane synthase and binds to the TXA2 receptors of nearby platelets, thereby serving as a potent platelet activator (modified from ref. 69). Figure created with Bio Render.com.

Back to article page